Andrea Iannone

Iannone at the [[Motorcycle Grand Prix of the Americas|2016 Grand Prix of the Americas]] Andrea Iannone (born 9 August 1989) is an Italian professional motorcycle racer who competed in the MotoGP World Championship from 2013 to 2019, and was a race winner in MotoGP, Moto2 and 125 cc World Championships.

He currently rides a Ducati in the World Superbike series.

Iannone returns to competition after serving a four-year ban for doping from 17 December 2019. He was initially given an 18-month ban by FIM and WADA which, after a failed appeal, was extended to four years by the Court of Arbitration for Sport. He has aspirations to return to racing in 2024, and has been contracted to race for satellite Ducati organisation Team GoEleven in World Superbikes, with his first official test at Jerez, Spain, in late October/early November 2023.

After winning four races in 125 cc World Championship and finishing 7th overall in Iannone made the move to Moto2 World Championship in . A further eight race wins and three consecutive third-place finishes followed in Moto2. And then Iannone made the move up to MotoGP in 2013 with Pramac Racing on a satellite Ducati. After spending two seasons with Pramac, Iannone was moved up to the Factory Ducati Team in . In Iannone managed to get three podiums, a Pole Position and what proved to be his best ever championship position and points tally of 5th and 188. A further four podiums and a Pole Position followed in including a maiden MotoGP win in Austria. After the arrival of triple MotoGP World Champion Jorge Lorenzo to Ducati Iannone made the move to Suzuki for 2017. After a difficult first season without a podium Iannone managed to get further four podium finishes with Suzuki in . Provided by Wikipedia
Showing 1 - 14 results of 14 for search 'Andrea Iannone', query time: 0.10s Refine Results
  1. 1
    A prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection: A further confirmation of "Geographic Weight"
    Get full text
    Article
  2. 2
    Chronic Viral Hepatitis in a Cohort of Inflammatory Bowel Disease Patients from Southern Italy: A Case-Control Study
    Get full text
    Article
  3. 3
    Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C
    Get full text
    Article
  4. 4
    The Spectrum of Small Intestinal Lesions in Patients with Unexplained Iron Deficiency Anemia Detected by Video Capsule Endoscopy
    Get full text
    Article
  5. 5
    Predictivity of Autoimmune Stigmata for Gluten Sensitivity in Subjects with Microscopic Enteritis: A Retrospective Study
    Get full text
    Article
  6. 6
    Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials
    Get full text
    Article
  7. 7
    Evaluation of Non-Celiac Gluten Sensitivity in Patients with Previous Diagnosis of Irritable Bowel Syndrome: A Randomized Double-Blind Placebo-Controlled Crossover Trial
    Get full text
    Article
  8. 8
    Seronegative Celiac Disease and Immunoglobulin Deficiency: Where to Look in the Submerged Iceberg?
    Get full text
    Article
  9. 9
    Inter-Observer Agreement of a New Endoscopic Score for Ulcerative Colitis Activity: Preliminary Experience
    Get full text
    Article
  10. 10
    T Helper Lymphocyte and Mast Cell Immunohistochemical Pattern in Nonceliac Gluten Sensitivity
    Get full text
    Article
  11. 11
    <i>Helicobacter pylori</i> Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy
    Get full text
    Article
  12. 12
    Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    Get full text
    Article
  13. 13
    Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    Get full text
    Article
  14. 14
    Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.
    by Loreta A Kondili, Giovanni Battista Gaeta, Maurizia Rossana Brunetto, Alfredo Di Leo, Andrea Iannone, Teresa Antonia Santantonio, Adele Giammario, Giovanni Raimondo, Roberto Filomia, Carmine Coppola, Daniela Caterina Amoruso, Pierluigi Blanc, Barbara Del Pin, Liliana Chemello, Luisa Cavalletto, Filomena Morisco, Laura Donnarumma, Maria Grazia Rumi, Antonio Gasbarrini, Massimo Siciliano, Marco Massari, Romina Corsini, Barbara Coco, Salvatore Madonia, Marco Cannizzaro, Anna Linda Zignego, Monica Monti, Francesco Paolo Russo, Alberto Zanetto, Marcello Persico, Mario Masarone, Erica Villa, Veronica Bernabucci, Gloria Taliani, Elisa Biliotti, Luchino Chessa, Maria Cristina Pasetto, Pietro Andreone, Marzia Margotti, Giuseppina Brancaccio, Donatella Ieluzzi, Guglielmo Borgia, Emanuela Zappulo, Vincenza Calvaruso, Salvatore Petta, Loredana Falzano, Maria Giovanna Quaranta, Liliana Elena Weimer, Stefano Rosato, Stefano Vella, Edoardo Giovanni Giannini
    Published 2017-01-01
    Get full text
    Article
Search Tools: Get RSS Feed — Email this Search